KEYMED BIO-B News

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024

Nov 1 04:36 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

Oct 2 04:34 ET

KEYMED BIO-B: 2024 INTERIM REPORT

Sep 23 09:01 ET

KEYMED BIO-B: INSIDE INFORMATION ANNOUNCEMENTSTAPOKIBART WAS GRANTED MARKETING APPROVAL FROMNATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THETREATMENT OF MODERATE-TO-SEVEREATOPIC DERMATITIS IN ADULTS

Sep 12 06:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Sep 2 04:54 ET

KEYMED BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

Aug 27 06:23 ET

KEYMED BIO-B: DATE OF BOARD MEETING

Aug 15 04:35 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024

Aug 2 04:35 ET

KEYMED BIO-B: INSIDE INFORMATION -EXCLUSIVE LICENSE AGREEMENTFOR CM512 AND CM536

Jul 8 20:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024

Jul 4 05:01 ET

KEYMED BIO-B: SIXTH AMENDED AND RESTATEDMEMORANDUM AND ARTICLES OF ASSOCIATION

Jun 25 08:14 ET

KEYMED BIO-B: POLL RESULTS OF THE ANNUAL GENERALMEETING HELD ON JUNE 25, 2024

Jun 25 08:06 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT RESULTS FROM AN EXPLORATORY CLINICAL STUDY OF CM313 IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA WERE RECENTLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Jun 19 20:15 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPSACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Jun 6 20:00 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024

Jun 5 04:43 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTLONG-TERM EFFICACY AND SAFETY DATA FROM A PHASE IIICLINICAL TRIAL OF STAPOKIBART INJECTION AT THEEUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY(EAACI) CONGRESS 2024

Jun 2 20:15 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTTHE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OFCMG901 (AZD0901) AT THE ASCO ANNUAL MEETING 2024 BY WAY OFORAL PRESENTATION

Jun 2 06:06 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTSTAPOKIBART INJECTION INCLUDED IN THE PRIORITYREVIEW AND APPROVAL PROCEDURES FOR THE TREATMENTOF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

May 23 04:30 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

May 6 04:34 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF SEASONAL ALLERGIC RHINITIS ACCEPTEDBY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Apr 29 20:15 ET